SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (1935)2/25/1999 11:17:00 AM
From: Steve Harmon  Respond to of 2742
 
Two contracts expire in April.

1)CEO galton's 5-year contract on April 30.
2)Genome's on April 3.



To: scaram(o)uche who wrote (1935)3/2/1999 11:45:00 PM
From: Steve Harmon  Respond to of 2742
 
Can you believe that Galton has been working for Cistron since 1985. Thats 14 plus years! He should have developed plenty of contacts over that time concerning Cistron's asset position.

Why the need for all of these investment bankers? He should have been able to make a deal by himself.



To: scaram(o)uche who wrote (1935)4/3/1999 3:22:00 PM
From: Steve Harmon  Respond to of 2742
 
There is a line of small and micro-cap biotech companies looking to pay a 20-30% premium for Cistron's cash alone.

That equates to a minimum of .70 cent a share just by the CEO saying "YES" to any offer.

So if we are paying a investment banker $1 million for the transaction what is your hypothesis on the sale price?

$1, $1.25?